Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 4/20 | 0.64 |
| ▸ | HTR4 | Q13639 | 13/20 | 0.55 |
| ▸ | KCNH2 | Q12809 | 3/20 | 0.53 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.52 |
| ▸ | HRH2 | P25021 | 1/20 | 0.52 |
| ▸ | HTR1D | P28221 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | HRH1 | P35367 | 1/20 | 0.52 |
| ▸ | HTR2B | P41595 | 1/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5793974 | 0.85 | HTR3A (0.58) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL7107763 | 0.83 | HTR4 (0.56) | HTR3AHTR4KCNH2 | |
| SCHEMBL17176553 | 0.82 | HTR3A (0.59) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL17170659 | 0.81 | HTR3A (0.57) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL17170656 | 0.79 | HTR3A (0.59) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL19068179 | 0.79 | HTR3A (0.56) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL8129547 | 0.79 | HTR3A (0.50) | HTR3AHTR4KCNH2CHRM2ADRA2B | |
| SCHEMBL7330863 | 0.78 | HTR4 (0.56) | HTR3AHTR4KCNH2 | |
| SCHEMBL17163321 | 0.78 | HTR3A (1.00) | HTR3AHTR4KCNH2 | |
| SCHEMBL15603679 | 0.78 | HTR3A (1.00) | HTR3AHTR4KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040192911-A1 | Process for the preparation of an indole derivative | SMITHKLINE BEECHAM P.L.C. | 2004-09-30 | — | — | US | claimed |
| EP-1097136-B1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | claimed |
| EP-0922048-B1 | PROCESS FOR THE PREPARATION OF N- (1-n-BUTYL-4-PIPERIDINYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-15 | — | — | EP | claimed |
| WO-2000017207-A1 | 3,4-DIHYDRO -N-[[1-(3 -HYDROXYBUTYL) -4-PIPERIDINYL] METHYL] -2H-[1,3] OXAZINO[3, 2-A]INDOLE -10-CARBOXAMIDE AS 5-HT(4) RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-03-30 | — | — | WO | claimed |
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| US-7834010-B2 | Modulators of peripheral 5-HT receptors | SERODUS AS (NO) | 2010-11-16 | — | — | US | disclosed |
| EP-1701951-B1 | MODULATORS OF PERIPHERAL 5-HT RECEPTORS | SERODUS AS (NO) | 2010-02-10 | — | — | EP | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| US-20090029979-A1 | 5-HTX MODULATORS | BIO-MEDISINSK INNOVASJON AS (NO) | 2009-01-29 | — | — | US | disclosed |
| EP-1097135-B1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | SMITHKLINE BEECHAM PLC (GB) | 2008-05-07 | — | — | EP | disclosed |
| US-20040176370-A1 | 3,4-Dihdro-N-[[1-(3-hydroxybutyl)-4-piperidinyl]methyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide as 5-HT(4) receptor antagonist | SMITHKLINE BEECHAM P.L.C. | 2004-09-09 | — | — | US | disclosed |
| EP-1097136-B1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | SMITHKLINE BEECHAM PLC (GB) | 2003-10-22 | — | — | EP | disclosed |
| US-6583294-B2 | Reacting 3-chloro-3-carboxylate indole with 3-chloropropanol in presence of such as trichloroacetic acid to produce methyl 2-(3-chloropropoxy)-indole-3-carboxylate in high yield | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-06-24 | — | — | US | disclosed |
| US-20030083506-A1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | SMITHKLINE BEECHAM P.L.C. | 2003-05-01 | — | — | US | disclosed |
| US-20020091271-A1 | Process for the preparation of an indole derivative | SMITHKLINE BEECHAM PLC | 2002-07-11 | — | — | US | disclosed |
| EP-0922048-B1 | PROCESS FOR THE PREPARATION OF N- (1-n-BUTYL-4-PIPERIDINYL)METHYL] -3,4-DIHYDRO -2H-[1,3] OXAZINO[3,2-a] INDOLE-10-CARBOXAMIDE AND SALTS AND INTERMEDIATES IN THE PROCESS | SMITHKLINE BEECHAM PLC (GB) | 2000-11-15 | — | — | EP | disclosed |
| US-6100397-A | Process for the preparation of N-[(1-n butyl-4-piperidyl)methyl]-3,4-dihydro-2H-[1,3]oxazino[3,2-a] indole-10-carboxamide and salts and intermediates in the process | SMITHKLINE BEECHAM PLC (GB) | 2000-08-08 | — | — | US | disclosed |
| WO-2000017207-A1 | 3,4-DIHYDRO -N-[[1-(3 -HYDROXYBUTYL) -4-PIPERIDINYL] METHYL] -2H-[1,3] OXAZINO[3, 2-A]INDOLE -10-CARBOXAMIDE AS 5-HT(4) RECEPTOR ANTAGONIST | SMITHKLINE BEECHAM P.L.C. (GB) | 2000-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090029979-A1 | 5-HTX MODULATORS | HTR7, HTR5A, HTR2C | HTR3A 7/4885HTR4 9/4885KCNH2 2040/4885 |
| US-20030083506-A1 | PROCESS FOR THE PREPARATION OF AN INDOLE DERIVATIVE | PRKD3, COMT, IDO1 | HTR3A 5/4885HTR4 63/4885KCNH2 1557/4885 |
| US-20040192911-A1 | Process for the preparation of an indole derivative | PRKD3, COMT, IDO1 | HTR3A 5/4885HTR4 63/4885KCNH2 1557/4885 |
| US-20040176370-A1 | 3,4-Dihdro-N-[[1-(3-hydroxybutyl)-4-piperidinyl]methyl]-2H-[1,3]oxazino[3,2-a]indole-10-carboxamide as 5-HT(4) receptor antagonist | HTR4, HTR3A, HTR1D | HTR3A 2/4885HTR4 1/4885KCNH2 469/4885 |
| US-20020091271-A1 | Process for the preparation of an indole derivative | PRKD3, COMT, IDO1 | HTR3A 5/4885HTR4 63/4885KCNH2 1557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.